CITATION REPORT List of articles citing

Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis

DOI: 10.1016/j.autrev.2015.05.011 Autoimmunity Reviews, 2015, 14, 875-9.

Source: https://exaly.com/paper-pdf/61230512/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 48 | The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation. <i>Journal of Immunology Research</i> , 2016 , 2016, 5183686 | 4.5 | 3 |
| 47 | First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. <i>Lupus Science and Medicine</i> , 2016 , 3, e000153 | 4.6 | 14 |
| 46 | Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. <i>Autoimmunity Reviews</i> , 2016 , 15, 656-63 | 13.6 | 35 |
| 45 | Autoimmunity in 2015. Clinical Reviews in Allergy and Immunology, 2016, 51, 110-9 | 12.3 | 6 |
| 44 | Old lines tell new tales: Blaschko linear lupus erythematosis. <i>Autoimmunity Reviews</i> , 2016 , 15, 291-306 | 13.6 | 17 |
| 43 | Adipose-Derived Mesenchymal Stem Cells in Autoimmune Disorders: State of the Art and Perspectives for Systemic Sclerosis. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 234-259 | 12.3 | 71 |
| 42 | International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 650-657 | 13.6 | 19 |
| 41 | Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. <i>Autoimmunity Reviews</i> , 2017 , 16, 826-832 | 13.6 | 38 |
| 40 | Paediatric systemic lupus erythematosus: insights from translational research. <i>Rheumatology</i> , 2017 , 56, i24-i31 | 3.9 | 3 |
| 39 | Biothfapies dans le lupus systfinique : de nouvelles cibles. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017 , 84, 23-30 | 0.1 | |
| 38 | Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage. <i>Lupus</i> , 2017 , 26, 598-605 | 2.6 | 9 |
| 37 | Biotherapies in systemic lupus erythematosus: New targets. <i>Joint Bone Spine</i> , 2017 , 84, 267-274 | 2.9 | 12 |
| 36 | Association between allelic variants of the human glucocorticoid receptor gene and autoimmune diseases: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2018 , 17, 449-456 | 13.6 | 8 |
| 35 | Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687 | 3.9 | 20 |
| 34 | Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. <i>Arthritis Care and Research</i> , 2018 , 70, 582-591 | 4.7 | 40 |
| 33 | Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort. <i>Lupus</i> , 2018 , 27, 2253-2261 | 2.6 | 23 |
| 32 | Can we treat systemic lupus erythematosus and other autoimmune diseases without oral steroids?. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 877-879 | 5.1 | 3 |

(2021-2018)

| 31 | FKBP51 modulates steroid sensitivity and NF B signalling: A novel anti-inflammatory drug target. <i>European Journal of Immunology</i> , 2018 , 48, 1904-1914 | 6.1 | 12 |
|----|---|---------------|-----|
| 30 | Corticosteroid dose and the risk of opportunistic infection in a national systemic lupus erythematosus cohort. <i>Lupus</i> , 2018 , 27, 1819-1827 | 2.6 | 21 |
| 29 | Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 482-489 | 5.3 | 30 |
| 28 | Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018 , 57, 1501-1502 | 3.9 | 1 |
| 27 | Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018 , 57, 1502-1503 | 3.9 | 7 |
| 26 | Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis. <i>International Urology and Nephrology</i> , 2019 , 51, 1805-1813 | 2.3 | 4 |
| 25 | Prolonged remission in SLE is possible by using reduced doses of prednisone: An observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. <i>Autoimmunity Reviews</i> , 2019 , 18, 102359 | 13.6 | 17 |
| 24 | 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 736-745 | 2.4 | 628 |
| 23 | New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 30-48 | 8.1 | 58 |
| 22 | Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020 , 59, v69-v81 | 3.9 | 16 |
| 21 | Glucocorticoids in . Ten Questions and Some Issues. <i>Journal of Clinical Medicine</i> , 2020 , 9, | 5.1 | 15 |
| 20 | Seventy years after Hench's Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. <i>Lupus</i> , 2020 , 29, 1155-1167 | 2.6 | 11 |
| 19 | Effect of prednisolone on glyoxalase 1 in an inbred mouse model of aristolochic acid nephropathy using a proteomics method with fluorogenic derivatization-liquid chromatography-tandem mass spectrometry. <i>PLoS ONE</i> , 2020 , 15, e0227838 | 3.7 | 5 |
| 18 | Systemic lupus erythematosus and infections. 2021 , 451-459 | | |
| 17 | Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020). <i>Archives of Osteoporosis</i> , 2021 , 16, 49 | 2.9 | 3 |
| 16 | Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. <i>Arthritis Care and Research</i> , 2021 , | 4.7 | 3 |
| 15 | [Deescalation and glucocorticoid-free treatment in SLE]. Zeitschrift Fur Rheumatologie, 2021, 80, 332-3 | 3 8 .9 | |
| 14 | Prednisone is genotoxic in mice and Drosophila melanogaster. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2021 , 865, 503334 | 3 | |

| 13 | Predicting lupus low disease activity state and remission in SLE: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1083-1089 | 5.1 | О |
|----|---|------|---|
| 12 | Novel Therapeutic Interventions in Systemic Lupus Erythematosus. | | |
| 11 | Eurolupus cyclophosphamide plus repeated pulses of methyl-prednisolone for the induction therapy of class III, IV and V lupus nephritis. <i>Autoimmunity Reviews</i> , 2021 , 20, 102898 | 13.6 | 1 |
| 10 | Glucocorticoids. 2021 , 611-622 | | |
| 9 | Treat-to-target in systemic lupus erythematosus: Where are we?. European Journal of Internal Medicine, 2020 , 74, 29-34 | 3.9 | 9 |
| 8 | According to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and comments. Nauchno-Prakticheskaya Revmatologiya, 2019 , 57, 496-510 | 0.9 | 3 |
| 7 | Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. <i>International Journal of Rheumatic Diseases</i> , 2021 , | 2.3 | 0 |
| 6 | Mechanism of Action and Efficacy of Immunosupressors in Lupus Nephritis <i>International Journal of Nephrology and Renovascular Disease</i> , 2021 , 14, 441-458 | 2.5 | 2 |
| 5 | Recent Advances in SLE Treatment Including Biologic Therapies. | | |
| 4 | Comparative effects of human-equivalent low, moderate, and high dose oral prednisone intake on autoimmunity and glucocorticoid-related toxicity in a murine model of environmental-triggered lupus. 13, | | O |
| 3 | Adherence to antimalarials and glucocorticoids treatment and its association with self-reported disease activity in systemic lupus erythematosus patients. 096120332211383 | | 0 |
| 2 | Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. 2023 , 59, 56 | | O |
| 1 | Lupus Recipe inhibits cGVHD-induced lupus nephritis in mice and promote renal LC3-associated autophagy. 2023 , 11, | | 0 |